To establish CD36 as a viable therapeutic target in AML, we investigated whether targeting CD36 has any detrimental impact on normal hematopoietic cells.<h4>Methods</h4>Differential expression data of CD36 during human and mouse normal hematopoiesis were examined and compared. Here, CD36 is linked to acute myeloid leukemia.